CAR-T treatment of relapsed refractory acute B lymphocytic leukemia with high remission rate December 14, 2018 Source: Science Network "After 110 patients with high-risk relapsed/refractory B-ALL who underwent CD19 CAR-T cell therapy, 92.7% of patients achieved complete or partial remission, and 87.3% of patients achieved complete MRD-negative remission." Beijing Ludaopei Hospital Zhang Xian, director of the Department of General Blood and Immunotherapy, said at the 60th Annual Meeting of the American Society of Hematology in 2018. For relapsed/refractory (B-ALL), the traditional treatment regimen is to perform allogeneic hematopoietic stem cell transplantation after completion of induction chemotherapy and consolidation enhancement, but traditional treatment methods are difficult to achieve minimal residual disease (MRD) negative remission. . According to previous reports, the disease-free survival rate of MRD-negative patients was significantly better than that of MRD-positive patients, and the risk of recurrence after transplantation was significantly lower than that of MRD-positive patients. Zhang string team study found that CD19 CAR-T cells in the treatment of B-ALL patients with a 1-year overall survival rate of 63.9%, recurrence-free survival rate of 70.5%. At the same time, the safety of the therapy was good. The incidence of grade 0~2 cytokine release syndrome (CRS) was 83%, and the incidence of grade 3~4 CRS was 17%. "The results of the study indicate that CD19 CAR-T cell therapy is a safe and effective treatment for patients with relapsed and refractory B-ALL. It also provides better long-term survival for bridged allogeneic hematopoietic stem cell transplantation after remission. " Zhang string said. The basis of immunotherapy is the body's immune system response and anti-tumor immune response, with the aim of enhancing the effectiveness and specificity of the body's immune system to attack tumors. Since T cells have the ability to directly proliferate and dissolve tumor cells, immunotherapy has brought new hope to B-ALL when traditional treatments such as chemotherapy and radiation therapy cannot solve all the problems of current B-ALL. Lu Peihua, director of medical treatment at Lu Daopei Hospital, introduced the study of 19 patients with refractory B-ALL who underwent CD19+CD22 double CAR-T cell infusion, 94.7% of patients achieved complete or partial remission, and 94.4% The patient achieved a negative MRD result. "Double CAR-T cell infusion is not only effective, but also safe. 95% of patients have only very mild CRS, and only 2 patients have neurotoxicity." Lu Peihua said, "And we found that CD19+CD22 Dual CAR-T achieves a higher complete response rate than single CD19 CAR-T treatment." According to reports, CD22 CAR is unique in that it can simultaneously secrete a ScFv fragment against PD-L1 monoclonal antibody, which can attempt to reduce the decline and failure of CAR-T cell activity by blocking the PD-1 / PD-L1 pathway. Thereby, the infused CAR-T cells have better functional activity and enhance the specific killing effect on tumor cells. Frozen Mussels,Frozen Cooked Clean Mussel Meat,Cooked Mussel Meat,Seafood Mussel Meat Shengsi Xiangyuan Aquatic Products Co.,Ltd., , https://www.xiangyuan-aquatic.com